Seattle Genetics, Daiichi Sankyo strike licensing deal

07/9/2008 |

Seattle Genetics has entered into a licensing agreement with Daiichi Sankyo Co. Ltd. for its "antibody drug conjugate" technology. The deal entitles the biotech firm to an upfront payment of $4 million and allows the Japanese drugmaker to use the technique to target an antigen found on various forms of solid tumors.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN